All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.

The GvHD Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

The ROCKstar study (KD025-213): What patients with chronic GvHD benefit most from belumosudil?

During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the GvHD Hub spoke to Steven Z. Pavletic, National Cancer Institute, Bethesda, US, about the ROCKstar study. We asked, What patients with chronic GvHD benefit most from belumosudil?

More effective and safe treatments are needed for chronic GvHD, one of the major and most difficult complications of allogeneic hematopoietic stem cell transplantation. In this video, Pavletic discusses the results of the phase II ROCKstar study, evaluating belumosudil in patients with moderate to severe chronic GvHD who failed two or more prior lines of therapy.

Read a summary of the phase II ROCKstar study, here.

Share:

Newsletter

Subscribe to get the best content related to GvHD delivered to your inbox